Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes.
Harrison
Leonard C
LC
Autoimmunity and Transplantation Division, The WalterEliza Hall Institute of Medical Research, 1G Royal Parade, Parkville 3050, Victoria, Australia. harrison@wehi.edu.au
Honeyman
Margo C
MC
Steele
Cheryl E
CE
Stone
Natalie L
NL
Sarugeri
Elena
E
Bonifacio
Ezio
E
Couper
Jennifer J
JJ
Colman
Peter G
PG
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D001327:Autoimmune Diseases / Q000517:prevention & control; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D002648:Child; D018592:Cross-Over Studies; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000008:administration & dosage*; D007330:Insulin Antibodies / Q000032:analysis* / Q000276:immunology; D007515:Islets of Langerhans / Q000187:drug effects*; D008297:Male; D009297:Nasal Mucosa / Q000187:drug effects; D011236:Prediabetic State / Q000188:drug therapy* / Q000276:immunology; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D001786:Blood Glucose; D007328:Insulin; D007330:Insulin Antibodies